Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 5/20 | 0.43 |
| ▸ | ADH1C | P00326 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9660873 | 1.00 | ADH1A (0.43) | ADH1AADH1CCYP1A2ADH4THRA | |
| SCHEMBL9658873 | 1.00 | ADH1A (0.43) | ADH1AADH1CCYP1A2ADH4THRA | |
| SCHEMBL9661149 | 0.98 | ADH1A (0.41) | ADH1AADH1CCYP1A2ADH4THRA | |
| SCHEMBL11166960 | 0.94 | ADH1A (0.42) | ADH1AADH1CCYP1A2ADH4THRA | |
| SCHEMBL304405 | 0.88 | ADH1A (0.50) | ADH1AADH1CCYP1A2THRATHRB | |
| SCHEMBL9660999 | 0.88 | ADH1A (0.50) | ADH1AADH1CCYP1A2THRATHRB | |
| SCHEMBL9660549 | 0.88 | ADH1A (0.50) | ADH1AADH1CCYP1A2THRATHRB | |
| SCHEMBL3024929 | 0.86 | ADH1A (0.48) | ADH1AADH1C | |
| SCHEMBL3448201 | 0.81 | ADH1A (0.39) | ADH1AADH1CCYP1A2ADH4THRA | |
| SCHEMBL302802 | 0.79 | ADH1A (0.47) | ADH1AADH1CL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255070-B2 | Method of deuteration using mixed catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-8093422-B2 | Method for deuteration of an aromatic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-1745002-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-19 | — | — | US | disclosed |
| US-7517990-B2 | Method for deuteration of a heterocyclic ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20070255076-A1 | Method for Deuteration of an Aromatic Ring | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1745002-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| EP-1707548-A1 | METHOD OF DEUTERATION USING MIXED CATALYST | Wako Pure Chemical Industries, Ltd. (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20060116535-A1 | Method of deuteration | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-20060025596-A1 | Method for deuteration or tritiation of heterocyclic ring | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2006-02-02 | — | — | US | disclosed |
| WO-2005105725-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| EP-1577280-A1 | METHOD OF DEUTERIZATION | Wako Pure Chemical Industries, Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1561741-A1 | METHOD FOR DEUTERATION OR TRITIATION OF HETEROCYCLIC RING | Wako Pure Chemical Industries, Ltd. (JP) | 2005-08-10 | — | — | EP | disclosed |
| EP-1535889-A1 | METHOD OF DEUTERATING AROMATIC RING | Wako Pure Chemical Industries, Ltd. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-0517262-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-12-09 | — | — | EP | disclosed |
| US-4585774-A | Aniline derivatives and cardiotonic composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| EP-0064878-B1 | NOVEL ANILINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND CARDIOTONIC COMPOSITIONS CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-07-24 | — | — | EP | disclosed |
| EP-0064878-A1 | Novel aniline derivatives, process for preparing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1982-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025596-A1 | Method for deuteration or tritiation of heterocyclic ring | HRH2, HRH4, HDHD5 | ADH1A 960/4885ADH1C 715/4885CYP1A2 624/4885 |
| US-20080234488-A1 | Method of Deuteration Using Mixed Catalyst | HDHD5, DHX35, HRH3 | ADH1A 1333/4885ADH1C 1044/4885CYP1A2 798/4885 |
| US-20070255076-A1 | Method for Deuteration of an Aromatic Ring | HRH3, HRH4, AHR | ADH1A 823/4885ADH1C 1127/4885CYP1A2 342/4885 |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | PPARG, PPARD, PPARA | ADH1A 322/4885ADH1C 570/4885CYP1A2 299/4885 |
| US-20060116535-A1 | Method of deuteration | ARL1, IDH2, IDH3A | ADH1A 302/4885ADH1C 186/4885CYP1A2 334/4885 |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | PPARG, PPARD, GPR119 | ADH1A 446/4885ADH1C 462/4885CYP1A2 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.